[ad_1]
(MENAFN – IANS)
New Delhi, September 12 (IANS) Bharat Biotech International Limited has announced that its Covid-19 vaccine candidate, COVAXIN, has shown positive efficacy in animal studies and has generated strong immune responses.
COVAXIN, developed by the Indian Council for Medical Research and Bharat Biotech, is being tested in 12 institutes in India. This indigenous vaccine is one of the pioneers in the race for a vaccine against the coronavirus in the country.
“Bharat Biotech proudly announces the results of the COVAXIN animal study; these results demonstrate protective efficacy in a live viral challenge model,” said the Hyderabad-based firm.
The drugmaker added: “The candidate vaccine was found to elicit strong immune responses. Therefore, it prevents infection and disease in primates with large amounts of exposure to the live SARS-CoV-2 virus.”
During the procedure, a two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered to 20 rhesus macaques, divided into four groups.
One group was given placebo, while three groups were immunized with three different candidate vaccines at zero and 14 days. All macaques were exposed to the viral challenge 14 days after the second dose.
“The results showed a protective efficacy, increasing the specific IgG of SARS-CoV-2 and neutralizing antibodies, reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkeys,” added Bharat Biotech.
No evidence of pneumonia was observed by histopathological examination in the vaccinated groups, unlike the placebo group. No adverse events were observed in animals immunized with a two-dose vaccination regimen.
–IANS
also known as / tsb
MENAFN1209202002310000ID1100785910
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, integrity, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this item, please contact the provider listed above.
